Amrinone
From Wikipedia, the free encyclopedia
 |
|
|
Amrinone
|
|
| Systematic (IUPAC) name | |
| 5-amino-3,4'-bipyridin-6(1H)-one | |
| Identifiers | |
| CAS number | |
| ATC code | C01 |
| PubChem | |
| Chemical data | |
| Formula | C10H9N3O |
| Mol. mass | 187.198 g/mol |
| Pharmacokinetic data | |
| Bioavailability | n/a |
| Protein binding | 10 to 49% |
| Metabolism | Hepatic |
| Half life | 5 to 8 hours |
| Excretion | Renal (63%) and fecal (18%) |
| Therapeutic considerations | |
| Pregnancy cat. |
C(US) |
| Legal status | |
| Routes | Intravenous |
Amrinone (INN) or inamrinone, trade name Inocor®, is a type 3 pyridine phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure.
| Selective Phosphodiesterase inhibitors (C01CE, G04BE) | |
|---|---|
| PDE1 | Vinpocetine |
| PDE2 | EHNA |
| PDE3 | Amrinone, Bucladesine, Enoximone, Milrinone |
| PDE4 | Mesembrine, Rolipram |
| PDE5 | Sildenafil, Tadalafil, Vardenafil |
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
